Pompano Beach, Dec. 4, 2013 (GLOBE NEWSWIRE) -- DS Healthcare Group Inc.(NASDAQ:DSKX), a leading developer of personal care products, announced that it has developed and will launch an over-the-counter neutraceutical tablet to combat premature hair thinning and improve healthy hair growth. Sold under the DS Laboratories brand, the tablet will complement and extend the company's industry-leading topical treatments, which promote longer, stronger, thicker hair.
The new DS Laboratories tablet will launch in Mexico during the first quarter of 2014. It will expand worldwide through the company's growing network of foreign markets. DS Laboratories products already sell in more than 15 countries as part of a rapid global expansion.
The new oral supplement employs a novel approach within the thinning-hair category -- complex peptides with potent antioxidants -- to maximize efficacy and potency. This formula results from ongoing clinical research at DS Healthcare Group on hair loss and related conditions.
"We've developed our own proprietary tablet, which contains a unique composition of ingredients, to achieve a real breakthrough in neutraceutical research," stated DS Healthcare President and CEO Daniel Khesin.
"Similar oral supplements already enjoy significant revenue in overseas markets where we have strong distribution. But none of the products we tested provided any real benefit to consumers. We have set out to improve this category, and we are very pleased with the outcome. Retailers worldwide have expressed great interest in our new tablet based on existing demand for competitors' products."
About DS Healthcare Group
DS Healthcare Group Inc. leads in the development and distribution of topical therapies for personal care, including what management believes is the world's most effective topical treatments for hair loss. Its products are sold through a network of salons, pharmacies, online retailers, specialty retailers, and select department stores. Its brands include DS Laboratories (www.DSLaboratories.com), Sigma Skin (www.SigmaSkin.com), Polaris Research Laboratories (www.PolarisResearchLabs.com), The Pure Guild (www.ThePureGuild.com), and Nutra Origin (www.NutraOrigin.com).
Except for statements of historical fact, the matters discussed in this press release are forward-looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies, and are generally preceded by words such as "future," "plan" or "planned," "expects," or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing and marketing products, intense competition, and additional risks factors as discussed in reports filed by the company with the Securities and Exchange Commission, which are available at http://www.sec.gov.
CONTACT: Contact: Laurel Moody Corporate Profile 1.646.810.0608
Source:DS Healthcare Group,Inc.